“Our collective hope shines a light on the progress made and challenges ahead,” CSL Behring Limited CEO and Managing Director Paul Perreault said in a…

King of Prussia’s biotherapeutics company CSL Behring is acquiring Calimmune, a clinical-stage biotechnology company, for $91 million, writes Linda Loyd for Philly.com…

Paul Perreault, the 59-year-old chief executive officer and managing director of CSL Ltd., recently discussed with the Philadelphia Inquirer the effect that gene…